Beneficial effects of leptin treatment in a setting of cardiac dysfunction induced by transverse aortic constriction in mouse

Journal of Physiology

Volumn 595, Issue 13, 2017, Pages 4227-4243

  Gómez Hurtado, Nieves ^a,b,f   Domínguez Rodríguez, Alejandro ^b,c   Mateo, Philippe ^b   Fernández Velasco, María ^d   Val Blasco, Almudena ^d   Aizpún, Rafael ^a   Sabourin, Jessica ^b   Gómez, Ana María ^b   Benitah, Jean Pierre ^b   Delgado, Carmen ^a,e  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Universite Paris Sud   (France)

^c Instituto de Biomedicina de Sevilla   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

heart failure; intracellular calcium; leptin

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; LEPTIN; LEPTIN RECEPTOR; RYANODINE RECEPTOR; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; CARDIOTONIC AGENT; KCNIP2 PROTEIN, MOUSE; KV CHANNEL INTERACTING PROTEIN; SHAL POTASSIUM CHANNEL;

ACTION POTENTIAL DURATION; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC CONSTRICTION; ARRHYTHMOGENESIS; ARTICLE; BODY MASS; BODY WEIGHT; BONE LENGTH; CAPACITANCE BLOOD VESSEL; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART CONTRACTION; HEART DEPOLARIZATION; HEART DISEASE; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HEART WEIGHT; M MODE ECHOCARDIOGRAPHY; MALE; MOUSE; NONHUMAN; OBESITY; PATCH CLAMP TECHNIQUE; PHENOTYPE; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TIBIA; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ACTION POTENTIAL; ANIMAL; AORTIC VALVE STENOSIS; C57BL MOUSE; CALCIUM SIGNALING; CELL CULTURE; DRUG EFFECTS; GENETICS; METABOLISM;

ACTION POTENTIALS; ANIMALS; AORTIC VALVE STENOSIS; CALCIUM SIGNALING; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOTONIC AGENTS; CELLS, CULTURED; KV CHANNEL-INTERACTING PROTEINS; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SHAL POTASSIUM CHANNELS;

EID: 85019568783     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP274030     Document Type: Article

References (81)

1. Abe Y, Ono K, Kawamura T, Wada H, Kita T, Shimatsu A & Hasegawa K (2007). Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 292, H2387–H2396.
2. Abel ED, Litwin SE & Sweeney G (2008). Cardiac remodeling in obesity. Physiol Rev 88, 389–419.
3. Ahrén B, Larsson H, Wilhelmsson C, Näsman B & Olsson T (1997). Regulation of circulating leptin in humans. Endocrine 7, 1–8.
4. Atkinson LL, Fischer MA & Lopaschuk GD (2002). Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 277, 29424–29430.
5. 2+-exchanger in heart failure. Cardiovasc Res 57, 986–995.
6. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP & Hare JM (2003). Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108, 754–759.
7. Benitah JP, Gomez AM, Bailly P, Da Ponte JP, Berson G, Delgado C & Lorente P (1993). Heterogeneity of the early outward current in ventricular cells isolated from normal and hypertrophied rat hearts. J Physiol 469, 111–138.
8. Bers DM (2002). Cardiac excitation-contraction coupling. Nature 415, 198–205.
9. Bers DM (2014). Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol 76, 107–127.
10. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 73, 379–385.
11. Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB & Mantzoros CS (2007). Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study. Diabetologia 50, 1178–1185.
12. + currents in adult mouse ventricular myocytes. J Physiol 559, 777–798.
13. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ & Bauer TL (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334, 292–295.
14. Curran J, Tang L, Roof SR, Velmurugan S, Millard A, Shonts S, Wang H, Santiago D, Ahmad U, Perryman M, Bers DM, Mohler PJ, Ziolo MT & Shannon TR (2014). Nitric oxide-dependent activation of CaMKII increases diastolic sarcoplasmic reticulum calcium release in cardiac myocytes in response to adrenergic stimulation. PLoS ONE 9, e87495.
15. 2+ oscillations. Science 279, 227–230.
16. Delgado C, Ruiz-Hurtado G, Gómez-Hurtado N, González-Ramos S, Rueda A, Benito G, Prieto P, Zaragoza C, Delicado EG, Pérez-Sen R, Miras-Portugal MT, Núñez G, Boscá L & Fernández-Velasco M (2015). NOD1, a new player in cardiac function and calcium handling. Cardiovasc Res 106, 375–386.
17. + pump rate in rat and rabbit ventricular myocytes. J Physiol 539, 133–143.
18. Dong F, Zhang X & Ren J (2006). Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 47, 222–229.
19. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ & Anderson ME (2008). A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462–474.
20. Fedak PW, Verma S, Weisel RD, Skrtic M & Li RK (2005). Cardiac remodeling and failure: from molecules to man (part III). Cardiovasc Pathol 14, 109–119.
21. Filippatos GS, Tsilias K, Venetsanou K, Karambinos E, Manolatos D, Kranidis A, Antonellis J, Kardaras F, Anthopoulos L & Baltopoulos G (2000). Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int J Cardiol 76, 117–122.
22. Fischer TH, Eiringhaus J, Dybkova N, Förster A, Herting J, Kleinwächter A, Ljubojevic S, Schmitto JD, Streckfuß-Bömeke K, Renner A, Gummert J, Hasenfuss G, Maier LS & Sossalla S (2014). Ca(2+) /calmodulin-dependent protein kinase II equally induces sarcoplasmic reticulum Ca(2+) leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail 16, 1292–1300.
23. 2+ leak in human cardiac pathology. Circulation 128, 970–981.
24. 2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 51, 760–768.
25. Gan XT, Zhao G, Huang CX, Rowe AC, Purdham DM & Karmazyn M (2013). Identification of fat mass and obesity associated (FTO) protein expression in cardiomyocytes: regulation by leptin and its contribution to leptin-induced hypertrophy. PLoS ONE 8, e74235.
26. Grueter CE, Colbran RJ & Anderson ME (2007). CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction. J Mol Med (Berl) 85, 5–14.
27. Guzmán-Ruiz R, Somoza B, Gil-Ortega M, Merino B, Cano V, Attané C, Castan-Laurell I, Valet P, Fernández-Alfonso MS & Ruiz-Gayo M (2010). Sensitivity of cardiac carnitine palmitoyltransferase to malonyl-CoA is regulated by leptin: similarities with a model of endogenous hyperleptinemia. Endocrinology 151, 1010–1018.
28. Gómez AM, Bénitah JP, Henzel D, Vinet A, Lorente P & Delgado C (1997). Modulation of electrical heterogeneity by compensated hypertrophy in rat left ventricle. Am J Physiol Heart Circ Physiol 272, H1078–H1086.
29. 2+ sparks in rat ventricular myocytes. J Physiol 496 (Pt 2), 575–581.
30. Gómez-Hurtado N, Fernández-Velasco M, Fernández-Alfonso MS, Boscá L & Delgado C (2014). Prolonged leptin treatment increases transient outward K⁺ current via upregulation of Kv4.2 and Kv4.3 channel subunits in adult rat ventricular myocytes. Pflügers Arch 466, 903–914.
31. Hall ME, Smith G, Hall JE & Stec DE (2012). Cardiomyocyte-specific deletion of leptin receptors causes lethal heart failure in Cre-recombinase-mediated cardiotoxicity. Am J Physiol Regul Integr Comp Physiol 303, R1241–R1250.
32. Hardie DG (2003). Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144, 5179–5183.
33. Hobai IA & O'Rourke B (2001). Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation 103, 1577–1584.
34. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA & Tillisch JH (2001). The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38, 789–795.
35. Ingwall JS (2009). Energy metabolism in heart failure and remodelling. Cardiovasc Res 81, 412–419.
36. Jäger S, Handschin C, St-Pierre J & Spiegelman BM (2007). AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 104, 12017–12022.
37. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB & Vasan RS (2002). Obesity and the risk of heart failure. N Engl J Med 347, 305–313.
38. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV & Ventura HO (2013). Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 1, 93–102.
39. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM & Kelly DP (2000). Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106, 847–856.
40. Lehnart SE, Maier LS & Hasenfuss G (2009). Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev 14, 213–224.
41. Leifheit-Nestler M, Wagner NM, Gogiraju R, Didié M, Konstantinides S, Hasenfuss G & Schäfer K (2013). Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity. J Transl Med 11, 170.
42. Littnerova S, Parenica J, Spinar J, Vitovec J, Linhart A, Widimsky P, Jarkovsky J, Miklik R, Spinarova L, Zeman K, Belohlavek J, Malek F, Felsoci M, Kettner J, Ostadal P, Cihalik C, Spac J, Al-Hiti H, Fedorco M, Fojt R, Kruger A, Malek J, Mikusová T, Monhart Z, Bohacova S, Pohludkova L, Rohac F, Vaclavik J, Vondrakova D, Vyskocilova K, Bambuch M & Dusek L (2015). Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure. PLoS ONE 10, e0117142.
43. Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW & Taylor HA (2010). Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol (Oxf) 72, 32–37.
44. Louch WE, Hougen K, Mørk HK, Swift F, Aronsen JM, Sjaastad I, Reims HM, Roald B, Andersson KB, Christensen G & Sejersted OM (2010). Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout. J Physiol 588, 465–478.
45. 2+ wave characteristics. Cell Calcium 34, 1–9.
46. Madani S, De Girolamo S, Muñoz DM, Li RK & Sweeney G (2006). Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 69, 716–725.
47. Mascareno E, Beckles D, Dhar-Mascareno M & Siddiqui MA (2009). Enhanced hypertrophy in ob/ob mice due to an impairment in expression of atrial natriuretic peptide. Vascul Pharmacol 51, 198–204.
48. McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, O'Doherty RM, McTiernan CF & O'Donnell CP (2008). Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res 77, 54–63.
49. McGaffin KR, Zou B, McTiernan CF & O'Donnell CP (2009). Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res 83, 313–324.
50. Mishra S, Harris TB, Hsueh WC, Hue T, Leak TS, Li R, Mehta M, Vaisse C & Sahyoun NR (2015). The association of serum leptin with mortality in older adults. PLoS ONE 10, e0140763.
51. Nakamura A, Rokosh DG, Paccanaro M, Yee RR, Simpson PC, Grossman W & Foster E (2001). LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 281, H1104–H1112.
52. Nattel S, Maguy A, Le Bouter S & Yeh YH (2007). Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87, 425–456.
53. Nerbonne JM & Kass RS (2005). Molecular physiology of cardiac repolarization. Physiol Rev 85, 1205–1253.
54. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM & McAlister FA (2008). Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 156, 13–22.
55. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, Perrier R, Soukaseum C, Nguyen Dinh Cat A, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B & Jaisser F (2005). Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025–3033.
56. Patel SP & Campbell DL (2005). Transient outward potassium current, ‘Ito’, phenotypes in the mammalian left ventricle: underlying molecular, cellular and biophysical mechanisms. J Physiol 569, 7–39.
57. Perrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gómez AM & Benitah JP (2004). Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110, 776–783.
58. i and contractility in nonfailing and failing human myocardium. Circulation 106, 447–453.
59. Pogwizd SM & Bers DM (2004). Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med 14, 61–66.
60. Rajapurohitam V, Gan XT, Kirshenbaum LA & Karmazyn M (2003). The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 93, 277–279.
61. Ravens U & Cerbai E (2008). Role of potassium currents in cardiac arrhythmias. Europace 10, 1133–1137.
62. Rider OJ, Petersen SE, Francis JM, Ali MK, Hudsmith LE, Robinson MR, Clarke K & Neubauer S (2011). Ventricular hypertrophy and cavity dilatation in relation to body mass index in women with uncomplicated obesity. Heart 97, 203–208.
63. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F & Lopez-Jimenez F (2006). Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368, 666–678.
64. Ruiz-Hurtado G, Gomez-Hurtado N, Fernandez-Velasco M, Calderon E, Smani T, Ordonez A, Cachofeiro V, Bosca L, Diez J, Gomez AM & Delgado C (2012). Cardiotrophin-1 induces sarcoplasmic reticulum Ca-2 leak and arrhythmogenesis in adult rat ventricular myocytes. Cardiovasc Res 96, 81–89.
65. Schaffer JE (2003). Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14, 281–287.
66. Schram K & Sweeney G (2008). Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med 18, 199–205.
67. 2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res 87, 50–59.
68. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R & Somers VK (2007). Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 100, 234–239.
69. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, Stephens TW & Caro JF (1996). Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 98, 1277–1282.
70. Soliman AT, Omar M, Assem HM, Nasr IS, Rizk MM, El Matary W & El Alaily RK (2002). Serum leptin concentrations in children with type 1 diabetes mellitus: relationship to body mass index, insulin dose, and glycemic control. Metabolism 51, 292–296.
71. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM & Lewandowski ED (2007). Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115, 2033–2041.
72. Stucchi P, Guzmán-Ruiz R, Gil-Ortega M, Merino B, Somoza B, Cano V, de Castro J, Sevillano J, Ramos MP, Fernández-Alfonso MS & Ruiz-Gayo M (2011). Leptin resistance develops spontaneously in mice during adult life in a tissue-specific manner. Consequences for hepatic steatosis. Biochimie 93, 1779–1785.
73. Sweeney G (2010). Cardiovascular effects of leptin. Nat Rev Cardiol 7, 22–29.
74. Tajmir P, Ceddia RB, Li RK, Coe IR & Sweeney G (2004). Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase- and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 145, 1550–1555.
75. Thøgersen AM, Söderberg S, Jansson JH, Dahlén G, Boman K, Nilsson TK, Lindahl B, Weinehall L, Stenlund H, Lundberg V, Johnson O, Ahrén B & Hallmans G (2004). Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil 11, 33–40.
76. Tomaselli GF & Marbán E (1999). Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42, 270–283.
77. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O & Sattar N (2014). The obesity paradox in men with coronary heart disease and heart failure: the role of muscle mass and leptin. Int J Cardiol 171, 49–55.
78. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A, Wallace AM & Sattar N (2007). Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 191, 418–426.
79. Xu FP, Chen MS, Wang YZ, Yi Q, Lin SB, Chen AF & Luo JD (2004). Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110, 1269–1275.
80. Zamora E, Díez-López C, Lupón J, de Antonio M, Domingo M, Santesmases J, Troya MI, Díez-Quevedo C, Altimir S & Bayes-Genis A (2016). Weight loss in obese patients with heart failure. J Am Heart Assoc 4, e002468.
81. + leak in normal and failing rabbit ventricular myocytes. J Physiol 588, 4743–4757.